Increased cyclin D1 expression in cancer of the ampulla of Vater: Relevance to nuclear β catenin accumulation and k-ras gene mutation

Journal of Clinical Pathology - Molecular Pathology

Volumn 56, Issue 6, 2003, Pages 336-341

  Yamazaki, K ^a   Hanami, K ^a   Nagao, T ^b   Asoh, A ^a   Sugano, I ^a   Ishida, Y ^a  

^a TEIKYO UNIVERSITY   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN D1; STEM CELL FACTOR;

ADULT; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME 11Q; CLINICAL ARTICLE; DRUG ACCUMULATION; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MISSENSE MUTATION; ONCOGENE C MYC; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN DEGRADATION; SURVIVAL TIME; TRANSACTIVATION; VATER PAPILLA CARCINOMA;

AGED; AMPULLA OF VATER; BETA CATENIN; COMMON BILE DUCT NEOPLASMS; CYCLIN D1; CYTOSKELETAL PROTEINS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POINT MUTATION; PROGNOSIS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0346244032     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.56.6.336     Document Type: Article

References (44)

1. Sherr CJ. Mammalian G1 cyclins. Cell 1993;73:1059-65.
2. Draetta G, Beach D. Activation of cdc2 protein kinase during mitosis in human cells: cell cycle-dependent phosphorylation and subunit rearrangement. Cell 1988;54:17-26.
3. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998;12:2245-62.
4. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
5. Jiang W, Kahn SM, Tomita N, et al. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 1992;52:2980-3.
6. Bartkova J, Lukas J, Muller H, et al. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994;57:353-61.
7. Gramlich TL, Fritsch CR, Maurer D, et al. Differential polymerase chain reaction assay of cyclin D1 gene amplification in esophageal carcinoma. Diagn Mol Pathol 1994;3:255-9.
8. Gillett C, Fantl V, Smith R, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994;54:1812-17.
9. Gansauge S, Gansauge F, Ramadani M, et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 1997;57:1634-7.
10. Ben-Ze'ev A, Geiger B. Differential molecular interactions of beta-catenin and plakoglobin in adhesion, signalling and cancer. Curr Opin Cell Biol 1998;10:629-39.
11. Morin PJ. Beta-catenin signalling and cancer. Bioessays 1999;21:1021-30.
12. Behrens J, Jerchow BA, Wurtele M, et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 1998;280:596-9.
13. Ikeda S, Kishida S, Yamamoto H, et al. Axin, a negative regulator of the Wnt signalling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J 1998;17:1371-84.
14. Hart MJ, de los Santos R, Albert IN, et al. Downregulation of beta-catenin by human axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol 1998;8:573-81.
15. Aberle H, Bauer A, Stappert J, et al. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997;16:3797-804.
16. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6.
17. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 1999;96:5522-7.
18. Lin SY, Xia W, Wang JC, et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 2000;97:4262-6.
19. Albanese C, Johnson J, Watanabe G, et al. Transforming p21 ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 1995;270:23589-97.
20. Arber N, Hibshoosh H, Moss SF, et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 1996;110:669-74.
21. Kawakami M, Kimura Y, Furuhata T, et al. Beta-catenin alteration in cancer of the ampulla of Vater. J Exp Clin Cancer Res 2002;21:23-7.
22. Zhao B, Kimura W, Futakawa N, et al. p53 and p21/Waf1 protein expression and K-ras codon 12 mutation in carcinoma of the papilla of Vater. Am J Gastroenterol 1999;94:2128-34.
23. Li X, Hui AM, Shi YZ, et al. Deregulation of G1/S transition is a common event in carcinoma of the ampulla of vater. Hepatogastroenterology 2002;49:1239-44.
24. Takashima M, Ueki T, Nagai E, et al. Carcinoma of the ampulla of Vater associated with or without adenoma: a clinicopathologic analysis of 198 cases with reference to p53 and Ki-67 immunohistochemical expressions. Mod Pathol 2000;13:1300-7.
25. Imai Y, Tsurutani N, Oda H, et al. p16INK4 gene mutations are relatively frequent in ampullary carcinomas. Jpn J Cancer Res 1997;88:941-6.
26. Imai Y, Oda H, Tsurutani N, et al. Frequent somatic mutations of the APC and p53 genes in sporadic ampullary carcinomas. Jpn J Cancer Res 1997;88:846-54.
27. Scarpa A, Capelli P, Zamboni G, et al. Neoplasia of the ampulla of Vater. Kiras and p53 mutations. Am J Pathol 1993;142:1163-72.
28. Matsubayashi H, Watanabe H, Yamaguchi T, et al. Differences in mucus and K-ras mutation in relation to phenotypes of tumors of the papilla of vater. Cancer 1999;86:596-607.
29. Albores-Saavedra J, Henson DE, Sobin LH. The WHO histological classification of tumors of the gallbladder and extrahepatic bile ducts. A commentary on the second edition. Cancer 1992;70:410-14.
30. Lundin J, Nordling S, von Boguslawsky K, et al. Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer. Anticancer Res 1995;15:2659-68.
31. Qiao Q, Ramadani M, Gansauge S, et al. Reduced membranous and ectopic cytoplasmic expression of beta-catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer. Int J Cancer 2001;95:194-7.
32. Younes N, Fulton N, Tanaka R, et al. The presence of K-12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors. Cancer 1997;79:1804-8.
33. Izzo JG, Papadimitrakopoulou VA, Liu DD, et al. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 2003;95:198-205.
34. Bartek J, Lukas L, Strauss M. [Control mechanisms of cell transition from the G1 phase to the S phase - the R point]. Cas Lek Cesk 1996;135:634-5.
35. Quelle DE, Ashmun RA, Shurtleff SA, et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 1993;7:1559-71.
36. Wong NA, Morris RG, McCondochie A, et al. Cyclin D1 overexpression in colorectal carcinoma in vivo is dependent on beta-catenin protein dysregulation, but not k-ras mutation. J Pathol 2002;197:128-35.
37. Ueta T, Ikeguchi M, Hirooka Y, et al. Beta-catenin and cyclin D1 expression in human hepatocellular carcinoma. Oncol Rep 2002;9:1197-203.
38. Sugimachi K, Aishima S, Taguchi K, et al. The role of overexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma. J Hepatol 2001;35:74-9.
39. Ito Y, Takeda T, Sasaki Y, et al. Expression and clinical significance of the G1-S modulators in intrahepatic cholangiocellular carcinoma. Oncology 2001;60:242-51.
40. Ito Y, Takeda T, Sasaki Y, et al. Expression of p57/Kip2 protein in extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma. Liver 2002;22:145-9.
41. Maruta H, Burgess AW. Regulation of the Ras signalling network. Bioessays 1994;16:489-96.
42. Chen CY, Liou J, Forman LW, et al. Differential regulation of discrete apoptotic pathways by Ras. J Biol Chem 1998;273:16700-9.
43. Rozakis-Adcock M, Fernley R, Wade J, et al. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature 1993;363:83-5.
44. Janes PW, Daly RJ, deFazio A, et al. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 1994;9:3601-8.